Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.72 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | CNR2 | P34972 | 2/20 | 0.49 |
| ▸ | CNR1 | P21554 | 3/20 | 0.46 |
| ▸ | HPGDS | O60760 | 3/20 | 0.46 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1386996 | 0.90 | LMNA (0.79) | LMNAGAAALDH1A1HPGDSTSHR | |
| Formaldehyde SCHEMBL27761965 | 0.86 | LMNA (0.73) | LMNAGAAALDH1A1HPGDSTSHR | |
| Ethylene SCHEMBL21647328 | 0.86 | LMNA (0.73) | LMNAGAAALDH1A1HPGDSTSHR | |
| SCHEMBL22408310 | 0.84 | LMNA (1.00) | LMNAGAAALDH1A1CNR2CNR1 | |
| SCHEMBL18010560 | 0.84 | LMNA (0.70) | LMNAGAAALDH1A1CNR2CNR1 | |
| Hydrochloric Acid SCHEMBL28055613 | 0.82 | LMNA (0.97) | LMNAGAAALDH1A1CNR2CNR1 | |
| SCHEMBL8940197 | 0.81 | LMNA (0.49) | LMNAGAAALDH1A1CNR2CNR1 | |
| SCHEMBL6429959 | 0.80 | LMNA (0.64) | LMNAGAAALDH1A1HPGDSTSHR | |
| SCHEMBL3461113 | 0.79 | LMNA (0.68) | LMNAGAAALDH1A1HPGDSTSHR | |
| SCHEMBL29181717 | 0.78 | LMNA (0.62) | LMNAGAAALDH1A1CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120196884-A1 | UREA SUBSTITUTED SULPHONAMIDE DERIVATIVES | BIOTIE THERAPIES CORPORATION (FI) | 2012-08-02 | — | — | US | disclosed |
| WO-2010146236-A1 | UREA SUBSTITUTED SULPHONAMIDE DERIVATIVES | BIOTIE THERAPIES CORP. (FI) | 2010-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120196884-A1 | UREA SUBSTITUTED SULPHONAMIDE DERIVATIVES | ITGA1, ITGB1, ITGA2B | LMNA 2594/4885GAA 4118/4885ALDH1A1 838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.